The Voluntary State Discount Prescription Drug Plan Act of 2009 would make it possible for states that negotiate for discounts under their Medicaid programs to extend those savings to anyone making up to 300% of the federal poverty level.
Allow states to negotiate lower prescription drug prices and extend Medicaid-negotiated discounts to low- and middle-income residents.
Occurrences
Evidence
Pingree's official House biography says that, as a Maine state senator, she sponsored MaineRX, one of the nation's first prescription drug pricing bills, and that after litigation it became law.
The Supreme Court syllabus describes Maine Rx as a program to reduce prescription drug prices for Maine residents by attempting to negotiate rebates with manufacturers, using Medicaid prior authorization pressure for nonparticipating companies.
Congress.gov records H.R. 3 as passed by the House on December 12, 2019. The bill would have required HHS to negotiate prices for certain prescription drugs and allowed negotiated prices to be offered beyond Medicare in some circumstances.
The Clerk records Roll Call 682 on H.R. 3 as passed, 230-192, on December 12, 2019; the roll-call listing records Rep. Chellie Pingree of Maine voting Yea.
Congress.gov records H.R. 5376 as Public Law 117-169. The law created Medicare prescription-drug negotiation and inflation rebate provisions, not a state Medicaid-discount extension program for low- and middle-income residents.
Congress.gov identifies Chellie Pingree as a House member from Maine's 1st District from the 111th through 119th Congresses, beginning in 2009.
Assessments
The specific federal promise was not fully delivered: no enacted federal program broadly allowed states to negotiate prescription drug prices and extend Medicaid-negotiated discounts to low- and middle-income non-Medicaid residents. Pingree had earlier state-level credit for Maine Rx, which resembled the policy, and later supported major federal drug-pricing efforts including H.R. 3. The Inflation Reduction Act later enacted Medicare drug-price negotiation and rebate provisions, advancing part of the broader prescription-drug affordability goal but not the state Medicaid-discount mechanism promised.